Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2021 | Aug. 12, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001653821 | |
Entity Registrant Name | CEN BIOTECH INC | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 000-55557 | |
Entity Incorporation, State or Country Code | A6 | |
Entity Address, Address Line One | 300-3295 Quality Way | |
Entity Address, City or Town | Windsor | |
Entity Address, Country | CA | |
Entity Address, Postal Zip Code | N8T 3R9 | |
City Area Code | 519 | |
Local Phone Number | 419-4958 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 47,673,933 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Current assets | ||
Cash and cash equivalents | $ 10,840 | $ 1,908 |
Prepaid expenses and other assets | 27,104 | 0 |
Loan receivable from Emergence Global Enterprises Inc. - related party | 0 | 17,901 |
Total current assets | 37,944 | 19,809 |
Other assets | ||
Other receivable | 24,629 | 113,999 |
Note receivable - CEN Biotech Ukraine LLC - related party | 44,859 | 44,859 |
Advances to CEN Biotech Ukraine LLC - related party | 1,299,328 | 1,179,328 |
Intangible assets, net | 4,743,741 | 4,956,147 |
Total assets | 6,150,501 | 6,314,142 |
Current liabilities | ||
Accounts payable | 262,529 | 190,716 |
Accounts payable – related parties | 8,347 | 8,347 |
Loans payable | 785,618 | 527,379 |
Loans payable – related parties | 1,314,395 | 1,363,354 |
Convertible notes payable | 2,115,390 | 6,652,448 |
Convertible notes payable- related parties | 2,419,983 | 2,558,681 |
Accrued interest | 1,295,080 | 1,125,034 |
Accrued interest – related parties | 1,720,575 | 1,615,880 |
Lease liabilities | 36,670 | 22,895 |
Accrued expenses | 705,633 | 641,023 |
Total current liabilities | 10,664,220 | 14,705,757 |
Operating lease liabilities, less current portion | 139,076 | 142,102 |
Patent acquisition liability | 302,000 | 1,380,000 |
Convertible notes, less current portion | 24,000 | 78,000 |
Total liabilities | 11,129,296 | 16,305,859 |
Shareholders’ deficit | ||
Common stock; unlimited authorized shares; 43,142,060 and 27,557,363 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively. No par value. | 0 | 0 |
Additional paid-in capital | 38,197,932 | 17,068,810 |
Accumulated deficit | (43,176,727) | (27,060,527) |
Total shareholders’ deficit | (4,978,795) | (9,991,717) |
Total liabilities and shareholders’ deficit | $ 6,150,501 | $ 6,314,142 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Common stock, par value (in dollars per share) | $ 0 | $ 0 |
Common stock, shares issued (in shares) | 43,142,060 | 27,557,363 |
Common stock, shares outstanding (in shares) | 43,142,060 | 27,557,363 |
Common stock, authorized | Unlimited | Unlimited |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Operating expenses | ||||
Consulting fees | $ 897,000 | $ 162,000 | $ 897,000 | $ 162,077 |
Consulting fees – related parties | 46,800 | 31,200 | 78,000 | 62,400 |
Stock based compensation | 14,925,572 | 196,650 | 15,001,322 | 393,300 |
General and administrative | 394,205 | 300,597 | 632,095 | 603,420 |
Total operating expenses | 16,263,577 | 690,447 | 16,608,417 | 1,221,197 |
Loss from operations | (16,263,577) | (690,447) | (16,608,417) | (1,221,197) |
Other income (expense) | ||||
Interest expense | (162,975) | (800,465) | (293,603) | (1,595,145) |
Interest expense – related parties | (113,414) | (106,059) | (236,650) | (211,510) |
Interest income | 0 | 1,853 | 394 | 3,912 |
Change in fair value of patent acquisition liability | 1,078,000 | 0 | 1,078,000 | 0 |
Foreign exchange (loss) gain | (31,199) | (64,763) | (55,924) | 63,947 |
Other income (expense), net | 770,412 | (969,434) | 492,217 | (1,738,796) |
Net loss | $ (15,493,165) | $ (1,659,881) | $ (16,116,200) | $ (2,959,993) |
Net loss per share: | ||||
Basic and diluted (in dollars per share) | $ (0.38) | $ (0.06) | $ (0.47) | $ (0.11) |
Weighted average number of shares outstanding | ||||
Basic and diluted (in shares) | 40,591,815 | 27,207,044 | 34,194,612 | 27,091,577 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($) | Conversion of Convertible Notes into Common Stock [Member]Common Stock [Member] | Conversion of Convertible Notes into Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Convertible Notes into Common Stock [Member]Retained Earnings [Member] | Conversion of Convertible Notes into Common Stock [Member] | Conversion of Related Party Convertible Notes into Common stock [Member]Common Stock [Member] | Conversion of Related Party Convertible Notes into Common stock [Member]Additional Paid-in Capital [Member] | Conversion of Related Party Convertible Notes into Common stock [Member]Retained Earnings [Member] | Conversion of Related Party Convertible Notes into Common stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balances (in shares) at Dec. 31, 2019 | 26,953,363 | |||||||||||
Balances at Dec. 31, 2019 | $ 0 | $ 15,775,010 | $ (41,310,172) | $ (25,535,162) | ||||||||
Stock-based compensation (in shares) | 0 | |||||||||||
Stock-based compensation | $ 0 | 393,300 | 0 | 393,300 | ||||||||
Issuance of common stock – interest shares (in shares) | 90,000 | |||||||||||
Issuance of common stock – interest shares | $ 0 | 64,800 | 0 | 64,800 | ||||||||
Issuance of common stock - consulting (in shares) | 225,000 | |||||||||||
Issuance of common stock - consulting | $ 0 | 162,000 | 0 | 162,000 | ||||||||
Issuance of common stock - settlement of accrued liability (in shares) | 0 | |||||||||||
Issuance of common stock - settlement of accrued liability | $ 0 | 58,500 | 0 | 58,500 | ||||||||
Net loss | $ 0 | 0 | (2,959,993) | (2,959,993) | ||||||||
Balances (in shares) at Jun. 30, 2020 | 27,268,363 | |||||||||||
Balances at Jun. 30, 2020 | $ 0 | 16,453,610 | (44,270,165) | (27,816,555) | ||||||||
Balances (in shares) at Mar. 31, 2020 | 26,998,363 | |||||||||||
Balances at Mar. 31, 2020 | $ 0 | 16,004,060 | (42,610,284) | (26,606,224) | ||||||||
Stock-based compensation (in shares) | 0 | |||||||||||
Stock-based compensation | $ 0 | 196,650 | 0 | 196,650 | ||||||||
Issuance of common stock – interest shares (in shares) | 45,000 | |||||||||||
Issuance of common stock – interest shares | $ 0 | 32,400 | 0 | 32,400 | ||||||||
Issuance of common stock - consulting (in shares) | 225,000 | |||||||||||
Issuance of common stock - consulting | $ 0 | 162,000 | 0 | 162,000 | ||||||||
Issuance of common stock - settlement of accrued liability (in shares) | 0 | |||||||||||
Issuance of common stock - settlement of accrued liability | $ 0 | 58,500 | 0 | 58,500 | ||||||||
Net loss | $ 0 | 0 | (1,659,881) | (1,659,881) | ||||||||
Balances (in shares) at Jun. 30, 2020 | 27,268,363 | |||||||||||
Balances at Jun. 30, 2020 | $ 0 | 16,453,610 | (44,270,165) | (27,816,555) | ||||||||
Balances (in shares) at Dec. 31, 2020 | 27,557,363 | |||||||||||
Balances at Dec. 31, 2020 | $ 0 | 17,068,810 | (27,060,527) | (9,991,717) | ||||||||
Stock-based compensation (in shares) | 11,409,291 | |||||||||||
Stock-based compensation | $ 0 | 15,001,322 | 0 | 15,001,322 | ||||||||
Issuance of common stock – interest shares (in shares) | 90,000 | |||||||||||
Issuance of common stock – interest shares | $ 0 | 103,350 | 0 | 103,350 | ||||||||
Issuance of common stock - consulting (in shares) | 650,000 | |||||||||||
Issuance of common stock - consulting | $ 0 | 897,000 | 0 | 897,000 | ||||||||
Issuance of common stock - settlement of accrued liability (in shares) | 8,369 | |||||||||||
Issuance of common stock - settlement of accrued liability | $ 0 | 13,390 | 0 | 13,390 | ||||||||
Net loss | 0 | 0 | (16,116,200) | (16,116,200) | ||||||||
Beneficial conversion feature on convertible notes issued | $ 0 | 111,306 | 0 | 111,306 | ||||||||
Issuance of common stock – upon conversion of convertible notes (in shares) | 3,290,180 | 42,500 | ||||||||||
Issuance of common stock – upon conversion of convertible notes | $ 0 | $ 4,855,861 | $ 0 | $ 4,855,861 | $ 0 | $ 68,000 | $ 0 | $ 68,000 | ||||
Issuance of common stock – settlement of accrued interest (in shares) | 94,357 | |||||||||||
Issuance of common stock – settlement of accrued interest | $ 0 | 78,893 | 0 | 78,893 | ||||||||
Balances (in shares) at Jun. 30, 2021 | 43,142,060 | |||||||||||
Balances at Jun. 30, 2021 | $ 0 | 38,197,932 | (43,176,727) | (4,978,795) | ||||||||
Balances (in shares) at Mar. 31, 2021 | 27,610,732 | |||||||||||
Balances at Mar. 31, 2021 | $ 0 | 17,220,050 | (27,683,562) | (10,463,512) | ||||||||
Stock-based compensation (in shares) | 11,409,291 | |||||||||||
Stock-based compensation | $ 0 | 14,925,572 | 0 | 14,925,572 | ||||||||
Issuance of common stock – interest shares (in shares) | 45,000 | |||||||||||
Issuance of common stock – interest shares | $ 0 | 41,250 | 0 | 41,250 | ||||||||
Issuance of common stock - consulting (in shares) | 650,000 | |||||||||||
Issuance of common stock - consulting | $ 0 | 897,000 | 0 | 897,000 | ||||||||
Net loss | 0 | 0 | (15,493,165) | (15,493,165) | ||||||||
Beneficial conversion feature on convertible notes issued | $ 0 | 111,306 | 0 | 111,306 | ||||||||
Issuance of common stock – upon conversion of convertible notes (in shares) | 3,290,180 | 42,500 | ||||||||||
Issuance of common stock – upon conversion of convertible notes | $ 0 | $ 4,855,861 | $ 0 | $ 4,855,861 | $ 0 | $ 68,000 | $ 0 | $ 68,000 | ||||
Issuance of common stock – settlement of accrued interest (in shares) | 94,357 | 94,357 | ||||||||||
Issuance of common stock – settlement of accrued interest | $ 0 | 78,893 | 0 | 78,893 | ||||||||
Balances (in shares) at Jun. 30, 2021 | 43,142,060 | |||||||||||
Balances at Jun. 30, 2021 | $ 0 | $ 38,197,932 | $ (43,176,727) | $ (4,978,795) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Cash flows from operating activities | ||
Net loss | $ (16,116,200) | $ (2,959,993) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation | 0 | 9,192 |
Amortization | 212,406 | 212,406 |
Amortization of debt discount | 75,755 | 0 |
Lease expense | 10,749 | 2,141 |
Stock-based compensation – employees | 15,001,322 | 393,300 |
Stock-based compensation – non-employees | 897,000 | 162,000 |
Shares issued for interest | 103,350 | 64,800 |
Change in fair value of patent acquisition liability | (1,078,000) | 0 |
Foreign exchange loss (gain) | 55,924 | (63,947) |
Changes in operating assets and liabilities which provided (used) cash | ||
Prepaid expenses and other assets | 8,075 | 0 |
Other receivable | 89,370 | 75,107 |
Accounts payable | 59,459 | 55,075 |
Accounts payable – related parties | 0 | 8,347 |
Accrued interest – related and non-related parties | 325,327 | 1,733,855 |
Accrued expenses | 78,000 | 62,400 |
Net cash used in operating activities | (277,463) | (245,317) |
Cash flows used in investing activities | ||
Advances to CEN Biotech Ukraine LLC | (120,000) | 0 |
Cash flows provided by financing activities | ||
Repayment of loans payable - related parties | (50,000) | 0 |
Issuance of convertible notes | 408,395 | 250,000 |
Issuance of convertible notes – related parties | 48,000 | 0 |
Net cash provided by financing activities | 406,395 | 250,000 |
Net increase in cash and cash equivalents | 8,932 | 4,683 |
Cash and cash equivalents, beginning of period | 1,908 | 3,757 |
Cash and cash equivalents, end of period | 10,840 | 8,440 |
Supplemental cash flows disclosures | ||
Cash paid for interest | 25,821 | 8,000 |
Non-cash transactions - investing and financing activities | ||
Issuance of common stock - settlement of interest | 78,893 | 0 |
Issuance of common stock - settlement of accrued liability | 13,390 | 58,500 |
Convertible Debt [Member] | ||
Non-cash transactions - investing and financing activities | ||
Debt Instrument, Convertible, Beneficial Conversion Feature | 111,306 | 0 |
Conversion of Convertible Notes into Common Stock [Member] | ||
Non-cash transactions - investing and financing activities | ||
Issuance of common stock – upon conversion of convertible notes | 4,855,861 | 0 |
Conversion of Related Party Convertible Notes into Common stock [Member] | ||
Non-cash transactions - investing and financing activities | ||
Issuance of common stock – upon conversion of convertible notes | $ 68,000 | $ 0 |
Note 1 - Basis of Presentation
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] | NOTE 1 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 X. not not December 31, 2020 There have been no 10 December 31, 2020. Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. three six June 30, 2021 2020, not Recent Developments In April 2021, no On April 19, 2021, April 19, 2021. April 19, 2021. April 19, 2021. April 19, 2021. On April 20, 2021, may no July 9, 2021 ( At Closing, the Company increased the number of members on its Board of Directors (the “Board”) by one At Closing, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Lehoux. Pursuant to the Employment Agreement, during the term of the Employment Agreement, the Company agreed to employ, and Mr. Lehoux agreed to accept employment with the Company as the Company’s Chief Technology Officer. Pursuant to the Employment Agreement, the Company agreed to pay Mr. Lehoux an annual base salary of $31,200. Recently Adopted Accounting Pronouncements No six June 30, 2021. Recent Accounting Pronouncements Not In August 2020, 2020 06 December 15, 2023. |
Note 2 - Going Concern Uncertai
Note 2 - Going Concern Uncertainty / Management Plans | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | NOTE 2 GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $43,176,727 at June 30, 2021 no not not 5, 6, 7, 8. 19 no not The Company’s cash position may not |
Note 3 - Advances to CEN Biotec
Note 3 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Advances to Related Party [Text Block] | NOTE 3 ADVANCES TO CEN BIOTECH UKRAINE AND LOAN RECEIVABLE FROM EMERGENCE GLOBAL At December 31, 2020, 11 December 31, 2021. not April 19, 2021. April 12, 2021. 402 2002, May 6, 2021, May 6, 2021. not At June 30, 2021 December 31, 2020, 11 Bahige (Bill) Chaaban, our Chief Executive Officer and member of our Board of Directors, and Usamakh Saadikh, a member of our Board of Directors, each directly own 25.5% of CEN Ukraine respectively. The remaining 49% of CEN Ukraine is owned by XN Pharma, which is an entity jointly owned by Bahige (Bill) Chaaban and Usamakh Saadikh. Bahige (Bill) Chaaban and Usamakh Saadikh do not not |
Note 4 - Intangible Assets
Note 4 - Intangible Assets | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | NOTE 4 INTANGIBLE ASSETS On September 12, 2016, August 31, 2016, Material consideration given by Company was: (a) Shares of CEN common stock equal to $5 million upon commencement of public trading (b) The transfer of real properties located at 135 1517 1525 The patent remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has not In March 2018, September 30, 2018. October 4, 2018, December 15, 2018. April 3, 2019, December 31, 2019. March 16, 2020 December 31, 2021. March 2018 June 30, 2021 December 31, 2020, The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no The intangible asset consists of the following at: June 30, 2021 December 31, 2020 Lighting patent $ 6,797,000 $ 6,797,000 Accumulated amortization (2,053,259 ) (1,840,853 ) Net $ 4,743,741 $ 4,956,147 As of June 30, 2021 December 31, 2020, 2031, 2032. |
Note 5 - Loans Payable
Note 5 - Loans Payable | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Short-term Debt [Text Block] | NOTE 5 LOANS PAYABLE Loans payable consist of the following at: June 30, 2021 December 31, 2020 Loan payable to Global Holdings International, LLC, which bears interest at 15% June 30, 2016 $ 75,000 $ 75,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD 385,000 22% November 21, 2018 310,618 302,379 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 August 16, 2021 50,000 50,000 Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 August 16, 2021 100,000 100,000 Loans payable in default to multiple private investors bearing an interest at rates of up to 5% June 2018 May 2021 250,000 - Total loans payable (all current) $ 785,618 $ 527,379 During each of the three June 30, 2021 2020, three June 30, 2021 2020, During each of the six June 30, 2021 2020, six June 30, 2021 2020, During the three June 30, 2021, |
Note 6 - Loans Payable - Relate
Note 6 - Loans Payable - Related Party | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Loans Payable to Related Party [Text Block] | NOTE 6 LOANS PAYABLE- RELATED PARTY Loans payable - related party consists of the following at: June 30, 2021 December 31, 2020 Loans payable in default to the spouse of Bill Chaaban, CEO of CEN, for the original amounts of CAD 48,630 198,660 10% December 31, 2018 $ 237,895 $ 236,854 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% December 31, 2018 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the CEO of CEN, bearing interest at 8% October 2, 2019 300,000 300,000 Loan payable to the spouse of Joseph Byrne, a 5% 4,000 August 16, 2021 100,000 100,000 Loan payable to Alex Tarrabain, CFO and a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 August 16, 2021 75,000 75,000 Loan payable to Joseph Byrne, a 5% 2,000 - 50,000 Total loans payable - related party (all current) $ 1,314,395 $ 1,363,354 Attributable related party accrued interest was $617,832 and $568,969 as of June 30, 2021 December 31, 2020, three June 30, 2021 2020, six June 30, 2021 2020, During both three June 30, 2021 2020, three June 30, 2021 2020, During both six June 30, 2021 2020, six June 30, 2021 2020, |
Note 7 - Convertible Notes
Note 7 - Convertible Notes | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | NOTE 7 CONVERTIBLE NOTES Convertible notes payable consists of the following at: June 30, 2021 December 31, 2020 Convertible note payable, due on demand, for the original amount of CAD 1,104,713 7% 335,833 $ 891,282 $ 867,641 Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% 776,467 May 2018 September 2022 1,236,794 5,862,807 Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at 5% 91,877 June 2022 30,562 - Total convertible notes payable 2,158,638 6,730,448 Less unamortized debt discount 19,248 - Total convertible notes payable, net of unamortized debt discount 2,139,390 6,730,448 Less current portion 2,115,390 6,652,448 Convertible notes payable, less current portion $ 24,000 $ 78,000 The Company issues convertible notes as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued during both the three six June 30, 2021 2021 three six June 30, 2020. These notes may During the three June 30, 2021, During the three June 30, 2021, As of August 12, 2021, |
Note 8 - Convertible Notes Paya
Note 8 - Convertible Notes Payable - Related Parties | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Long-term Convertible Notes Related Party [Text Block] | NOTE 8 CONVERTIBLE NOTES PAYABLE - RELATED PARTIES Convertible notes payable - related parties consists of the following at: June 30, 2020 December 31, 2020 Convertible note in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12% 867,576 August 17, 2020 $ 1,388,122 $ 1,388,122 Convertible notes in default due to Harold Aubrey de Lavenu, a Vice President and Director of CEN, bearing interest at 5% 548,980 March 31, 2019 878,368 878,368 Convertible notes in default due to Joseph Byrne, former CEO, and current President and member of the board of CEN, bearing interest at 12% 76,123 August 17, 2020 121,796 224,191 Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at 5% 48,000 May 24, 2022 48,000 - Convertible note in default due to Alex Tarrabain, CFO and a Director of CEN, bearing interest at 5% 30,000 - 48,000 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Vice President and a Director of CEN, bearing interest at 5% 12,500 - 20,000 Total convertible notes payable – related parties 2,436,286 2,558,681 Less unamortized debt discount 16,303 - Total convertible notes payable - related parties (all current) $ 2,419,983 $ 2,558,681 Attributable related party accrued interest was $1,102,743 and $1,046,911 as of June 30, 2021 December 31, 2020, three June 30, 2021 2020, six June 30, 2021 2020, The Company issues convertible notes to related parties as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued to related parties during both the three six June 30, 2021 2021 three six June 30, 2020. These notes may During the three June 30, 2021, As of August 12, 2021, |
Note 9 - Income Taxes
Note 9 - Income Taxes | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 9 INCOME TAXES A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the three six June 30: 2021 2020 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 %) (26.5 %) Effective income tax rate 0 % 0 % As of June 30, 2021, may 20 2034. may not not June 30, 2021 December 31, 2020: June 30, 2021 December 31, 2020 Deferred tax asset - net operating losses $ 7,600,000 $ 3,400,000 Deferred tax asset valuation allowance (7,600,000 ) (3,400,000 ) Net deferred tax asset $ - $ - The valuation allowance increased $4,100,000 and $600,000 for the three June 30, 2021 2020, six June 30, 2021 2020, Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of June 30, 2021, no no no 2017. |
Note 10 - Shareholders' Deficit
Note 10 - Shareholders' Deficit / Stock Activity | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 10 SHAREHOLDERS DEFICIT / STOCK ACTIVITY The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no stated par value. As of June 30, 2021, |
Note 11 - Related Party Transac
Note 11 - Related Party Transactions | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE 11 RELATED PARTY TRANSACTIONS The Company has received loans from several related parties, as described above in Notes 6 8. A loan totaling $17,901 was made to Emergence Global as of December 31, 2020. July 2017 November 13, 2019. May 6, 2021, 3. There are advances of $1,299,328 and $1,179,328 to CEN Biotech Ukraine as of June 30, 2021 December 31, 2020, 4. December 3, 2017, December 14, 2017, not August 12, 2021, not not On July 12, 2017, During the three June 30, 2021 2020, six June 30, 2021 2020, June 30, 2021 December 31, 2020, During 2017, 10 2017 2026. No June 30, 2021, Jamaal Shaban (“Lessor”), cousin of Bill Chaaban, leased 20 10.4 two January 2017 five third October 2019. August 1, 2020, August 1, 2020 three six June 30, 2020, The Company also leased office space in Windsor, Ontario from R&D Labs Canada, Inc., whose president is Bill Chaaban. This lease was subsequently assigned to RN Holdings Ltd, a third May 8, 2019 October 1, 2017, September 2022, August 1, 2020, no August 1, 2020. August 12, 2021, not June 30, 2021 June 30, 2021 December 31, 2020 three June 30, 2021 2020, three June 30, 2021 2020, Effective with the August 1, 2020 Maturities of the operating lease liability for the 12 June 30, 2021 Amount 2022 $ 48,392 2023 30,927 2024 32,820 2025 32,820 2026 32,820 Thereafter 41,025 Total lease payments $ 218,804 Less imputed interest 43,058 Present value of lease liability $ 175,746 |
Note 12 - Stock Based Compensat
Note 12 - Stock Based Compensation | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | NOTE 12 STOCK BASED COMPENSATION Adoption of Equity Compensation Plan On November 29, 2017, 2017 On April 2, 2021, 2021 “2021 2021 Equity Compensation Grants On November 30, 2017, one 36 36 On October 1, 2019, On April 17, 2020, three On August 27, 2020 September 25, 2020, two On April 2, 2021, 12 Employment Agreements On November 30, 2017, four ● Under the Employment Agreement with Bahige (Bill) Chaaban, then President of the Company, Mr. Chaaban agreed to receive compensation in the form of a base annual salary of $31,200 and a grant of 8,750,000 shares of restricted stock of the Company, of which 7,400,000 vested immediately and the remaining vested ratably each month over the next 36 November 2020. ● Under the Employment Agreement with Joseph Byrne, former Chief Executive Officer of the Company, Mr. Byrne agreed to receive compensation in the form of a base annual salary of $31,200 and a grant of 1,250,000 shares of restricted stock of the Company, of which 325,000 vested immediately and the remaining vesting ratably each month over the next 36 November 2020. November 13, 2019, April 2, 2020, not April 19, 2021, ● Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and then Chief Financial Officer of the Company, Mr. Boswell agreed to receive compensation in the form of a base annual salary of $31,200 and a grant of 4,500,000 shares of restricted stock of the Company, of which 4,140,000 vested immediately and the remaining vested ratably each month over the next 36 November 2020. ● Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne agreed to receive compensation in the form of a base annual salary of $31,200 36 November 2020. On May 16, 2019, one one May 21, 2019 ( July 2017, In conjunction with the above, on May 16, 2019, ● Under the Employment Agreement with Alex Tarrabain, Chief Financial Officer and as one 36 May 2022. On April 2, 2021, On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021, 2021 On April 2, 2021 June 25, 2021, 2021 Restricted Stock Awards Restricted stock awards relate to common shares that are subject to applicable securities laws and regulations as set forth in the RSAs and other equity compensation grants. The total grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $28,760,063 and $13,013,241 as of June 30, 2021 December 31, 2020, three six June 30, 2021, three six June 30, 2020, April 5, 2021 April 5, 2021, With the exception of immediately vesting portions of awards, shares typically vest pro-rata over the requisite service period, which is generally three During the three June 30, 2021 2020, six June 30, 2021 2020, 1,237,500, three June 30, 2021 2020, six June 30, 2021 2020, Compensation expense recognized in connection with the restricted stock awards was $14,925,572 and $196,650 for the three June 30, 2021 2020, six June 30, 2021 2020, three six June 30, 2021 2020, Non-vested restricted stock award activity for the six June 30, 2021 2020 Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2020 2,025,000 $ 0.76 1.54 Granted 225,000 0.72 - Vested (1,237,500 ) 0.68 - Forfeited - - - Non-vested at June 30, 2020 1,012,500 $ 0.84 1.35 Non-vested at January 1, 2021 425,000 $ 1.01 1.50 Granted 12,059,291 1.31 - Vested (12,209,291 ) 1.30 - Forfeited - - - Non-vested at June 30, 2021 275,000 $ 1.01 1.00 The fair value of the restricted stock grants was based on the valuation of a third April 5, 2021. April 5, 2021, June 30, 2021, May 2022. |
Note 13 - Net Loss Per Share
Note 13 - Net Loss Per Share | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | NOTE 13 NET LOSS PER SHARE During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of June 30, 2021 2020. three six June 30, 2021 2020 Three-months Ended June 30, Six-months Ended June 30, 2021 2020 2021 2020 Convertible debt 2,657,697 5,482,166 2,631,484 5,376,040 |
Note 14 - Contingency
Note 14 - Contingency | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 14 CONTINGENCY In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 10 May 4, 2016 5 not |
Note 15 - Fair Value Disclosure
Note 15 - Fair Value Disclosures | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | NOTE 15 FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows at: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At June 30, 2021: Cash and cash equivalents $ 10,840 $ - $ 10,840 $ - $ 10,840 Other receivables $ 24,629 $ - $ - $ 24,629 $ 24,629 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 785,618 $ - $ - $ 785,618 $ 785,618 Loans payable – related parties $ 1,314,395 $ - $ - $ - $ - Patent acquisition liability $ 302,000 $ 302,000 $ - $ - $ 302,000 Convertible notes payable $ 2,139,390 $ - $ - $ 3,328,714 $ 3,328,714 Convertible notes payable – related parties $ 2,419,983 $ - $ - $ - $ - Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 1,908 $ - $ 1,908 $ - $ 1,908 Other receivables $ 113,999 $ - $ - $ 113,999 $ 113,999 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to Emergence Global - related party $ 17,901 $ - $ - $ 17,901 $ 17,901 Advances to CEN Biotech Ukraine, LLC - related party $ 1,179,328 $ - $ - $ 1,179,328 $ 1,179,328 Loans payable $ 527,379 $ - $ - $ 527,379 $ 527,379 Loans payable – related parties $ 1,363,354 $ - $ - $ - $ - Patent acquisition liability $ 1,380,000 $ - $ - $ 1,380,000 $ 1,380,000 Convertible notes payable $ 6,730,448 $ - $ - $ 7,766,663 $ 7,766,663 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - The fair values of other receivables (including related accrued interest), note receivable - CEN Biotech Ukraine, LLC, and advances to Emergence Global and CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments. The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates. The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates. It is not The fair value of the patent acquisition liability is based upon the fair value of the common stock, which was obtained from a 3 rd April 5, 2021. April 5, 2021, 3 1 |
Note 16 - Subsequent Events
Note 16 - Subsequent Events | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 16 SUBSEQUENT EVENTS From July 1, 2021 August 12, 2021, 4 4 From July 1, 2021 August 12, 2021, 1 On July 13, 2021, 2021 On July 13, 2021, 2021 On April 20, 2021, may no July 9, 2021 ( one |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Earnings Per Share, Policy [Policy Text Block] | Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. three six June 30, 2021 2020, not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Pronouncements No six June 30, 2021. Recent Accounting Pronouncements Not In August 2020, 2020 06 December 15, 2023. |
Note 4 - Intangible Assets (Tab
Note 4 - Intangible Assets (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | June 30, 2021 December 31, 2020 Lighting patent $ 6,797,000 $ 6,797,000 Accumulated amortization (2,053,259 ) (1,840,853 ) Net $ 4,743,741 $ 4,956,147 |
Note 5 - Loans Payable (Tables)
Note 5 - Loans Payable (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Short-term Debt [Table Text Block] | June 30, 2021 December 31, 2020 Loan payable to Global Holdings International, LLC, which bears interest at 15% June 30, 2016 $ 75,000 $ 75,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD 385,000 22% November 21, 2018 310,618 302,379 Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 August 16, 2021 50,000 50,000 Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 August 16, 2021 100,000 100,000 Loans payable in default to multiple private investors bearing an interest at rates of up to 5% June 2018 May 2021 250,000 - Total loans payable (all current) $ 785,618 $ 527,379 |
Note 6 - Loans Payable - Rela_2
Note 6 - Loans Payable - Related Party (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Loans Payable to Related Party [Table Text Block] | June 30, 2021 December 31, 2020 Loans payable in default to the spouse of Bill Chaaban, CEO of CEN, for the original amounts of CAD 48,630 198,660 10% December 31, 2018 $ 237,895 $ 236,854 Loans payable in default to a former director of Creative, former parent company, bear interest at 10% December 31, 2018 601,500 601,500 Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the CEO of CEN, bearing interest at 8% October 2, 2019 300,000 300,000 Loan payable to the spouse of Joseph Byrne, a 5% 4,000 August 16, 2021 100,000 100,000 Loan payable to Alex Tarrabain, CFO and a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 August 16, 2021 75,000 75,000 Loan payable to Joseph Byrne, a 5% 2,000 - 50,000 Total loans payable - related party (all current) $ 1,314,395 $ 1,363,354 |
Note 7 - Convertible Notes (Tab
Note 7 - Convertible Notes (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Long-term Debt Instruments [Table Text Block] | June 30, 2021 December 31, 2020 Convertible note payable, due on demand, for the original amount of CAD 1,104,713 7% 335,833 $ 891,282 $ 867,641 Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% 776,467 May 2018 September 2022 1,236,794 5,862,807 Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at 5% 91,877 June 2022 30,562 - Total convertible notes payable 2,158,638 6,730,448 Less unamortized debt discount 19,248 - Total convertible notes payable, net of unamortized debt discount 2,139,390 6,730,448 Less current portion 2,115,390 6,652,448 Convertible notes payable, less current portion $ 24,000 $ 78,000 |
Note 8 - Convertible Notes Pa_2
Note 8 - Convertible Notes Payable - Related Parties (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Convertible Notes Payable to Related Party [Table Text Block] | June 30, 2020 December 31, 2020 Convertible note in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at 12% 867,576 August 17, 2020 $ 1,388,122 $ 1,388,122 Convertible notes in default due to Harold Aubrey de Lavenu, a Vice President and Director of CEN, bearing interest at 5% 548,980 March 31, 2019 878,368 878,368 Convertible notes in default due to Joseph Byrne, former CEO, and current President and member of the board of CEN, bearing interest at 12% 76,123 August 17, 2020 121,796 224,191 Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at 5% 48,000 May 24, 2022 48,000 - Convertible note in default due to Alex Tarrabain, CFO and a Director of CEN, bearing interest at 5% 30,000 - 48,000 Convertible note due to Darren Ferris, brother of Ameen Ferris, a Vice President and a Director of CEN, bearing interest at 5% 12,500 - 20,000 Total convertible notes payable – related parties 2,436,286 2,558,681 Less unamortized debt discount 16,303 - Total convertible notes payable - related parties (all current) $ 2,419,983 $ 2,558,681 |
Note 9 - Income Taxes (Tables)
Note 9 - Income Taxes (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2021 2020 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 %) (26.5 %) Effective income tax rate 0 % 0 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | June 30, 2021 December 31, 2020 Deferred tax asset - net operating losses $ 7,600,000 $ 3,400,000 Deferred tax asset valuation allowance (7,600,000 ) (3,400,000 ) Net deferred tax asset $ - $ - |
Note 11 - Related Party Trans_2
Note 11 - Related Party Transactions (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Amount 2022 $ 48,392 2023 30,927 2024 32,820 2025 32,820 2026 32,820 Thereafter 41,025 Total lease payments $ 218,804 Less imputed interest 43,058 Present value of lease liability $ 175,746 |
Note 12 - Stock Based Compens_2
Note 12 - Stock Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Nonvested Restricted Stock Shares Activity [Table Text Block] | Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2020 2,025,000 $ 0.76 1.54 Granted 225,000 0.72 - Vested (1,237,500 ) 0.68 - Forfeited - - - Non-vested at June 30, 2020 1,012,500 $ 0.84 1.35 Non-vested at January 1, 2021 425,000 $ 1.01 1.50 Granted 12,059,291 1.31 - Vested (12,209,291 ) 1.30 - Forfeited - - - Non-vested at June 30, 2021 275,000 $ 1.01 1.00 |
Note 13 - Net Loss Per Share (T
Note 13 - Net Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three-months Ended June 30, Six-months Ended June 30, 2021 2020 2021 2020 Convertible debt 2,657,697 5,482,166 2,631,484 5,376,040 |
Note 15 - Fair Value Disclosu_2
Note 15 - Fair Value Disclosures (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Fair Value, by Balance Sheet Grouping [Table Text Block] | Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At June 30, 2021: Cash and cash equivalents $ 10,840 $ - $ 10,840 $ - $ 10,840 Other receivables $ 24,629 $ - $ - $ 24,629 $ 24,629 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 1,299,328 $ - $ - $ 1,299,328 $ 1,299,328 Loans payable $ 785,618 $ - $ - $ 785,618 $ 785,618 Loans payable – related parties $ 1,314,395 $ - $ - $ - $ - Patent acquisition liability $ 302,000 $ 302,000 $ - $ - $ 302,000 Convertible notes payable $ 2,139,390 $ - $ - $ 3,328,714 $ 3,328,714 Convertible notes payable – related parties $ 2,419,983 $ - $ - $ - $ - Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2020: Cash and cash equivalents $ 1,908 $ - $ 1,908 $ - $ 1,908 Other receivables $ 113,999 $ - $ - $ 113,999 $ 113,999 Note receivable – CEN Biotech Ukraine, LLC – related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to Emergence Global - related party $ 17,901 $ - $ - $ 17,901 $ 17,901 Advances to CEN Biotech Ukraine, LLC - related party $ 1,179,328 $ - $ - $ 1,179,328 $ 1,179,328 Loans payable $ 527,379 $ - $ - $ 527,379 $ 527,379 Loans payable – related parties $ 1,363,354 $ - $ - $ - $ - Patent acquisition liability $ 1,380,000 $ - $ - $ 1,380,000 $ 1,380,000 Convertible notes payable $ 6,730,448 $ - $ - $ 7,766,663 $ 7,766,663 Convertible notes payable – related parties $ 2,558,681 $ - $ - $ - $ - |
Note 1 - Basis of Presentatio_2
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) | Jul. 09, 2021 | Apr. 20, 2021 |
Chief Technology Officer [Member] | Subsequent Event [Member] | ||
Annual Salary | $ 31,200 | |
Clear Com Media, Inc [Member] | ||
Share Exchange Agreement, Shares to Acquire (in shares) | 10,000 | |
Share Exchange Agreement, Shares to Issue (in shares) | 4,000,000 |
Note 2 - Going Concern Uncert_2
Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (43,176,727) | $ (27,060,527) |
Note 3 - Advances to CEN Biot_2
Note 3 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global (Details Textual) - USD ($) | May 06, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 02, 2017 |
Notes Receivable, Related Parties, Current | $ 0 | $ 17,901 | ||
Emergence Global [Member] | ||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.82 | |||
Former CEO [Member] | ||||
Ownership Percentage | 5.00% | |||
CEN Biotech Ukraine [Member] | ||||
Notes Receivable, Related Parties, Current | $ 17,901 | |||
Due from Related Parties, Total | $ 1,299,328 | 1,179,328 | ||
Percentage of Related Party's Equity Interest Owned by Director | 51.00% | |||
CEN Biotech Ukraine [Member] | Usamakh Saadikh [Member] | ||||
Ownership Percentage | 49.00% | |||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% | |||
Emergence Global [Member] | ||||
Notes Receivable, Related Parties, Current | $ 17,901 | |||
Notes Receivable, Original Amount Converted to Common Stock | $ 17,901 | |||
Notes Receivable, Converted Instrument, Shares Received as Payment (in shares) | 21,830 |
Note 4 - Intangible Assets (Det
Note 4 - Intangible Assets (Details Textual) - USD ($) | Apr. 03, 2019 | Sep. 12, 2016 | Mar. 31, 2018 | Jun. 30, 2021 | Sep. 30, 2018 | Dec. 31, 2020 |
Stock Issued During Period, Value, Purchase of Assets | $ 5,000,000 | |||||
Development of Acquired Technology, Annual Compensation for Specialist | $ 200,000 | |||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Liability Incurred | $ 4,380,000 | |||||
Contingent Consideration Classified as Equity, Fair Value Disclosure | $ 302,000 | $ 1,380,000 | ||||
Impairment of Real Estate | $ 0 | $ 0 | ||||
Finite-Lived Intangible Asset, Useful Life (Year) | 16 years | |||||
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year | $ 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Two | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Three | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Four | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Five | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Six | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Seven | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Eight | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Nine | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Ten | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year One | 424,812 | |||||
Finite-Lived Intangible Asset, Expected Amortization, Year Eleven | $ 283,215 | |||||
Tesla Digital [Member] | ||||||
Stock Issued During Period, Shares, Purchase of Assets (in shares) | 1,000,000 | |||||
Patented Technology [Member] | ||||||
Stock Issued During Period, Value, Purchase of Assets | 5,000,000 | |||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred | 2,161,467 | |||||
Noncash or Part Noncash Acquisition, Noncash Consideration, Original Cost of Property Transferred | $ 202,666 |
Note 4 - Intangible Assets - In
Note 4 - Intangible Assets - Intangible Assets (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Lighting patent | $ 6,797,000 | $ 6,797,000 |
Accumulated amortization | (2,053,259) | (1,840,853) |
Net | $ 4,743,741 | $ 4,956,147 |
Note 5 - Loans Payable (Details
Note 5 - Loans Payable (Details Textual) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021USD ($)shares | Jun. 30, 2020USD ($)shares | Jun. 30, 2021USD ($)shares | Jun. 30, 2020USD ($)shares | |
Stock Issued During Period, Value, New Issues | $ 41,250 | $ 32,400 | $ 103,350 | $ 64,800 |
Short-term Loan Payable to Multiple Investors [Member] | ||||
Convertible Debt, Total | $ 250,000 | $ 250,000 | ||
Debt Instrument, Convertible, Number of Equity Instruments | 128,125 | |||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 0 | |||
Individual Lenders [Member] | ||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 18,000 | 18,000 | 36,000 | 36,000 |
Stock Issued During Period, Value, New Issues | $ 16,500 | $ 12,960 | $ 41,340 | $ 25,920 |
Note 5 - Loans Payable - Loans
Note 5 - Loans Payable - Loans Payable (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Loan payable | $ 785,618 | $ 527,379 |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Loan payable | 75,000 | 75,000 |
Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
Loan payable | 310,618 | 302,379 |
Short-term Loan Payable to an Individual [Member] | ||
Loan payable | 50,000 | 50,000 |
Second Short-term Loan Payable to an Individual [Member] | ||
Loan payable | 100,000 | 100,000 |
Short-term Loan Payable to Multiple Investors [Member] | ||
Loan payable | $ 250,000 | $ 0 |
Note 5 - Loans Payable - Loan_2
Note 5 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
Interest Rate | 15.00% | 15.00% |
Maturity Date | Jun. 30, 2016 | Jun. 30, 2016 |
Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
Interest Rate | 22.00% | 22.00% |
Maturity Date | Nov. 21, 2018 | Nov. 21, 2018 |
Original Amount | $ 385,000 | $ 385,000 |
Short-term Loan Payable to an Individual [Member] | ||
Maturity Date | Aug. 16, 2021 | Aug. 16, 2021 |
Share Interest (in shares) | 2,000 | 2,000 |
Second Short-term Loan Payable to an Individual [Member] | ||
Maturity Date | Aug. 16, 2021 | Aug. 16, 2021 |
Share Interest (in shares) | 4,000 | 4,000 |
Short-term Loan Payable to Multiple Investors [Member] | ||
Interest Rate | 5.00% | 5.00% |
Maturity Date, start | Jun. 1, 2018 | Jun. 1, 2018 |
Maturity Date, end | May 31, 2021 | May 31, 2021 |
Note 6 - Loans Payable - Rela_3
Note 6 - Loans Payable - Related Party (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Interest Expense, Related Party | $ 113,414 | $ 106,059 | $ 236,650 | $ 211,510 | |
Stock Issued During Period, Value, New Issues | $ 41,250 | $ 32,400 | $ 103,350 | $ 64,800 | |
Related Parties Lenders [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 27,000 | 27,000 | 54,000 | 54,000 | |
Stock Issued During Period, Value, New Issues | $ 24,750 | $ 19,440 | $ 62,010 | $ 38,880 | |
Loans Payable to Related Party [Member] | |||||
Interest Payable, Related Party | 617,832 | 617,832 | $ 568,969 | ||
Interest Expense, Related Party | $ 51,662 | $ 46,188 | $ 115,524 | $ 91,771 |
Note 6 - Loans Payable - Rela_4
Note 6 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Long-term Debt, Total | $ 1,314,395 | $ 1,363,354 |
Bill Chaaban, President of Cen Biotech [Member] | ||
Long-term Debt, Total | 237,895 | 236,854 |
Creative Edge [Member] | ||
Long-term Debt, Total | 601,500 | 601,500 |
R&D Labs Canada, Inc [Member] | ||
Long-term Debt, Total | 300,000 | 300,000 |
Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||
Long-term Debt, Total | 100,000 | 100,000 |
Director, Alex Tarrabain [Member] | ||
Long-term Debt, Total | 75,000 | 75,000 |
Joseph Byrne [Member] | ||
Long-term Debt, Total | $ 0 | $ 50,000 |
Note 6 - Loans Payable - Rela_5
Note 6 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2021USD ($)shares | Dec. 31, 2020USD ($)shares | Jun. 30, 2021CAD ($)shares | Dec. 31, 2020CAD ($)shares | |
Joseph Byrne [Member] | ||||
Related Party Interest | 5.00% | 5.00% | ||
Loans Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member] | ||||
Interest Rate | 10.00% | 10.00% | 10.00% | 10.00% |
Maturity Date | Dec. 31, 2018 | Dec. 31, 2018 | ||
Original Amount | $ 198,660 | $ 198,660 | $ 48,630 | $ 48,630 |
Loans Payable to Related Party [Member] | Creative Edge [Member] | ||||
Interest Rate | 10.00% | 10.00% | 10.00% | 10.00% |
Maturity Date | Dec. 31, 2018 | Dec. 31, 2018 | ||
Loans Payable to Related Party [Member] | R&D Labs Canada, Inc [Member] | ||||
Interest Rate | 8.00% | 8.00% | 8.00% | 8.00% |
Maturity Date | Oct. 2, 2019 | Oct. 2, 2019 | ||
Loans Payable to Related Party [Member] | Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||||
Maturity Date | Aug. 16, 2021 | Aug. 16, 2021 | ||
Share Interest (in shares) | 4,000 | 4,000 | 4,000 | 4,000 |
Related Party Interest | 5.00% | 5.00% | 5.00% | 5.00% |
Loans Payable to Related Party [Member] | Director, Alex Tarrabain [Member] | ||||
Maturity Date | Aug. 16, 2021 | Aug. 16, 2021 | ||
Share Interest (in shares) | 3,000 | 3,000 | 3,000 | 3,000 |
Loans Payable to Related Party [Member] | Joseph Byrne [Member] | ||||
Share Interest (in shares) | 2,000 | 2,000 | 2,000 | 2,000 |
Related Party Interest | 5.00% | 5.00% | 5.00% | 5.00% |
Note 7 - Convertible Notes (Det
Note 7 - Convertible Notes (Details Textual) | Aug. 12, 2021USD ($) | Aug. 12, 2021USD ($) | Jun. 30, 2021USD ($)shares | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) |
Subsequent Event [Member] | ||||||
Debt Instrument, Convertible, Number of Equity Instruments | 52,631 | |||||
Conversion of Convertible Notes into Common Stock [Member] | ||||||
Debt Conversion, Original Debt, Amount | $ 4,855,861 | |||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 3,290,180 | |||||
Debt Conversion, Accrued Interest, Amount | $ 78,893 | |||||
Stock Issued During Period, Shares, Settlement of Accrued Interest (in shares) | shares | 94,357 | |||||
Convertible Debt Payable to Non-related Party [Member] | ||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 93,164 | $ 93,164 | ||||
Convertible Debt [Member] | ||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 0 | $ 111,306 | $ 0 | |||
Debt Instrument, Convertible, Number of Equity Instruments | 1,204,177 | |||||
Convertible Debt [Member] | Subsequent Event [Member] | ||||||
Debt Instrument, Convertible, Number of Equity Instruments | 619,167 | |||||
Debt Instrument, Debt Default, Amount | $ 985,111 | $ 985,111 |
Note 7 - Convertible Notes - Co
Note 7 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Long-term Debt, gross | $ 2,158,638 | $ 6,730,448 |
Less unamortized debt discount | 19,248 | 0 |
Long-term Debt, Total | 2,139,390 | 6,730,448 |
Less current portion | 2,115,390 | 6,652,448 |
Convertible notes payable, less current portion | 24,000 | 78,000 |
Convertible Notes 1[Member] | ||
Long-term Debt, gross | 891,282 | 867,641 |
Convertible Notes 2 [Member] | ||
Long-term Debt, gross | 1,236,794 | 5,862,807 |
Convertible Notes 3 [Member] | ||
Long-term Debt, gross | $ 30,562 | $ 0 |
Note 7 - Convertible Notes - _2
Note 7 - Convertible Notes - Convertible Notes (Details) (Parentheticals) - Convertible Debt [Member] | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021CAD ($) | Dec. 31, 2020CAD ($) | |
Conversion Rights | 1,204,177 | |
Convertible Notes 1[Member] | ||
Interest Rate | 7.00% | 7.00% |
Conversion Rights | 335,833 | 335,833 |
Original Amount | $ 1,104,713 | $ 1,104,713 |
Convertible Notes 2 [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 776,467 | 776,467 |
Maturity Date, start | May 1, 2018 | May 1, 2018 |
Maturity Date, end | Sep. 30, 2022 | Sep. 30, 2022 |
Convertible Notes 3 [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 91,877 | 91,877 |
Maturity Date | Jun. 30, 2022 | Jun. 30, 2022 |
Note 8 - Convertible Notes Pa_3
Note 8 - Convertible Notes Payable - Related Parties (Details Textual) | Aug. 12, 2021USD ($) | Aug. 12, 2021USD ($) | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Dec. 31, 2020USD ($) |
Interest Expense, Related Party | $ 113,414 | $ 106,059 | $ 236,650 | $ 211,510 | |||
Subsequent Event [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 52,631 | ||||||
Convertible Debt Payable to Related Party [Member] | |||||||
Interest Payable, Related Party | 1,102,743 | 1,102,743 | $ 1,046,911 | ||||
Interest Expense, Related Party | 61,752 | 59,871 | 121,126 | 119,739 | |||
Debt Instrument, Convertible, Beneficial Conversion Feature | 18,142 | $ 0 | $ 18,142 | $ 0 | |||
Debt Instrument, Convertible, Number of Equity Instruments | 1,587,167 | ||||||
Long-term Debt, Total | $ 2,419,983 | $ 2,419,983 | $ 2,558,681 | ||||
Convertible Debt Payable to Related Party [Member] | Subsequent Event [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 1,492,679 | ||||||
Debt Instrument, Debt Default, Amount | $ 2,388,287 | $ 2,388,287 | |||||
Convertible Debt Payable to Related Party [Member] | Joseph Byrne [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 76,123 | 76,123 | |||||
Convertible Debt Payable to Related Party Reclassified to Private Investor [Member] | Joseph Byrne [Member] | |||||||
Debt Instrument, Convertible, Number of Equity Instruments | 63,997 | ||||||
Long-term Debt, Total | $ 102,395 | $ 102,395 |
Note 8 - Convertible Notes Pa_4
Note 8 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Long-term Debt, gross | $ 2,436,286 | $ 2,558,681 |
Less unamortized debt discount | 16,303 | 0 |
Long-term Debt | 2,419,983 | 2,558,681 |
Bill Chaaban, President of Cen Biotech [Member] | ||
Long-term Debt, gross | 1,388,122 | 1,388,122 |
Director, Harold Aubrey de Lavenu [Member] | ||
Long-term Debt, gross | 878,368 | 878,368 |
Joseph Byrne [Member] | ||
Long-term Debt, gross | 121,796 | 224,191 |
Jeff Thomas [Member] | ||
Long-term Debt, gross | 48,000 | 0 |
Director, Alex Tarrabain [Member] | ||
Long-term Debt, gross | 0 | 48,000 |
Brother of Director Ameen Ferris [Member] | ||
Long-term Debt, gross | $ 0 | $ 20,000 |
Note 8 - Convertible Notes Pa_5
Note 8 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals) - Convertible Debt Payable to Related Party [Member] | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Conversion Rights | 1,587,167 | |
Bill Chaaban, President of Cen Biotech [Member] | ||
Interest Rate | 12.00% | 12.00% |
Conversion Rights | 867,576 | 867,576 |
Maturity Date | Aug. 17, 2020 | Aug. 17, 2020 |
Director, Harold Aubrey de Lavenu [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 548,980 | 548,980 |
Maturity Date | Mar. 31, 2019 | Mar. 31, 2019 |
Joseph Byrne [Member] | ||
Interest Rate | 12.00% | 12.00% |
Conversion Rights | 76,123 | 76,123 |
Maturity Date | Aug. 17, 2020 | Aug. 17, 2020 |
Jeff Thomas [Member] | ||
Interest Rate | 5.00% | 5.00% |
Conversion Rights | 48,000 | 48,000 |
Maturity Date | May 24, 2022 | May 24, 2022 |
Director, Alex Tarrabain [Member] | ||
Interest Rate | 5.00% | |
Conversion Rights | 30,000 | |
Brother of Director Ameen Ferris [Member] | ||
Interest Rate | 5.00% | |
Conversion Rights | 12,500 |
Note 9 - Income Taxes (Details
Note 9 - Income Taxes (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Operating Loss Carryforwards, Total | $ 28,900,000 | $ 28,900,000 | ||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 4,100,000 | $ 600,000 | $ 4,200,000 | $ 700,000 |
Note 9 - Income Taxes - Reconci
Note 9 - Income Taxes - Reconciliation of Effective Tax Rate (Details) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Income tax benefit at Canadian statutory rate | 26.50% | 26.50% |
Valuation allowance | (26.50%) | (26.50%) |
Effective income tax rate | 0.00% | 0.00% |
Note 9 - Income Taxes - Deferre
Note 9 - Income Taxes - Deferred Tax Assets (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Deferred tax asset - net operating losses | $ 7,600,000 | $ 3,400,000 |
Deferred tax asset valuation allowance | (7,600,000) | (3,400,000) |
Net deferred tax asset | $ 0 | $ 0 |
Note 10 - Shareholders' Defic_2
Note 10 - Shareholders' Deficit / Stock Activity (Details Textual) - $ / shares $ / shares in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Common Stock, No Par Value (in dollars per share) | $ 0 | $ 0 |
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 2,791,344 |
Note 11 - Related Party Trans_3
Note 11 - Related Party Transactions (Details Textual) | Aug. 01, 2020USD ($)shares | Oct. 01, 2017CAD ($) | Sep. 30, 2022CAD ($) | Jan. 31, 2017CAD ($) | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Dec. 31, 2017USD ($) | Dec. 31, 2020USD ($) | Dec. 14, 2017 | Dec. 02, 2017 | Jul. 12, 2017 |
Notes Receivable, Related Parties, Current | $ 0 | $ 0 | $ 17,901 | ||||||||||
Operating Lease, Liability, Total | $ 175,746 | $ 175,746 | |||||||||||
Lease Arrangement, 20 North Rear Road [Member] | |||||||||||||
Operating Lease, Monthly Rent | $ 4,000 | ||||||||||||
Lessee, Operating Lease, Term of Contract (Year) | 5 years | ||||||||||||
Stock Issued During Period, Shares, Issued for Settlement of Lease Termination (in shares) | shares | 36,500 | ||||||||||||
Stock Issued During Period, Value, Issued for Settlement of Lease Termination | $ 50,700 | ||||||||||||
Lessee, Operating Lease, Discount Rate | 8.00% | ||||||||||||
Operating Lease, Right-of-Use Asset | $ 48,110 | ||||||||||||
Operating Lease, Liability, Total | 45,118 | ||||||||||||
Gain (Loss) on Termination of Lease | (53,692) | ||||||||||||
Operating Lease, Expense | $ 8,690 | $ 17,409 | |||||||||||
Leases Office Space from R&D Labs Canada, Inc [Member] | |||||||||||||
Operating Lease, Monthly Rent | $ 2,608 | ||||||||||||
Lessee, Operating Lease, Discount Rate | 8.00% | 8.00% | |||||||||||
Operating Lease, Liability, Total | $ 175,746 | $ 175,746 | 164,997 | ||||||||||
Operating Lease, Expense | $ 5,577 | 6,928 | $ 10,749 | 13,253 | |||||||||
Operating Lease, Impairment Loss | $ 146,795 | ||||||||||||
Leases Office Space from R&D Labs Canada, Inc [Member] | Forecast [Member] | |||||||||||||
Operating Lease, Monthly Rent | $ 3,390 | ||||||||||||
Long-term Convertible Notes Payable to Multiple Private Investors [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | ||||||||||||
CEN Biotech Ukraine [Member] | XN Pharma [Member] | |||||||||||||
Ownership Percentage | 49.00% | ||||||||||||
CEN Biotech Ukraine [Member] | |||||||||||||
Percentage of Related Party's Equity Interest Owned by Director | 25.50% | ||||||||||||
Business Acquisition, Percentage of Voting Interests Acquired | 51.00% | ||||||||||||
Emergence Global [Member] | |||||||||||||
Notes Receivable, Related Parties, Current | 17,901 | ||||||||||||
Joseph Byrne [Member] | |||||||||||||
Percentage of Related Party's Equity Interest Owned | 5.00% | 5.00% | |||||||||||
CEN Biotech Ukraine [Member] | |||||||||||||
Notes Receivable, Related Parties, Current | 17,901 | ||||||||||||
Due from Related Parties, Total | $ 1,299,328 | $ 1,299,328 | 1,179,328 | ||||||||||
Percentage of Related Party's Equity Interest Owned by Director | 51.00% | ||||||||||||
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member] | |||||||||||||
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | $ 255,141 | ||||||||||||
Notes Receivable, Related Parties | 44,859 | ||||||||||||
Board Members and Officers [Member] | Consulting Fees [Member] | |||||||||||||
Related Party Transaction, Amounts of Transaction | 46,800 | $ 31,200 | 78,000 | $ 62,400 | |||||||||
Due to Related Parties, Total | $ 408,200 | $ 408,200 | $ 330,200 | ||||||||||
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member] | |||||||||||||
Notes Payable, Related Parties | $ 300,000 |
Note 11 - Related Party Trans_4
Note 11 - Related Party Transactions - Future Minimum Operating Lease Payments (Details) | Jun. 30, 2021USD ($) |
2022 | $ 48,392 |
2023 | 30,927 |
2024 | 32,820 |
2025 | 32,820 |
2026 | 32,820 |
Thereafter | 41,025 |
Total lease payments | 218,804 |
Less imputed interest | 43,058 |
Present value of lease liability | $ 175,746 |
Note 12 - Stock Based Compens_3
Note 12 - Stock Based Compensation (Details Textual) - USD ($) | Jun. 25, 2021 | Apr. 02, 2021 | Sep. 25, 2020 | Aug. 27, 2020 | Apr. 17, 2020 | Apr. 02, 2020 | Oct. 01, 2019 | May 16, 2019 | Nov. 30, 2017 | Jun. 30, 2021 | Jun. 25, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Nov. 29, 2017 |
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 2,791,344 | 2,791,344 | ||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 162,500 | 162,500 | 225,000 | 50,000 | ||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 162,000 | $ 897,000 | $ 162,000 | $ 897,000 | $ 162,000 | |||||||||||
President [Member] | ||||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 8,750,000 | |||||||||||||||
President [Member] | Vested Immediately [Member] | ||||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 7,400,000 | |||||||||||||||
Chief Executive Officer [Member] | ||||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 1,250,000 | |||||||||||||||
Accrued Salaries | $ 58,500 | |||||||||||||||
Number of Restricted Shares to settle Accrued Salaries (in shares) | 337,500 | |||||||||||||||
Chief Executive Officer [Member] | Vested Immediately [Member] | ||||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 325,000 | |||||||||||||||
Senior Executive Vice President and Chief Financial Officer [Member] | ||||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 4,500,000 | |||||||||||||||
Senior Executive Vice President and Chief Financial Officer [Member] | Vested Immediately [Member] | ||||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 4,140,000 | |||||||||||||||
Vice President [Member] | ||||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 750,000 | |||||||||||||||
Vice President [Member] | Vested Immediately [Member] | ||||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 300,000 | |||||||||||||||
Chief Financial Officer [Member] | ||||||||||||||||
Employment Agreement, Base Annual Salary | $ 31,200 | |||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 1,250,000 | |||||||||||||||
Chief Financial Officer [Member] | Vested Immediately [Member] | ||||||||||||||||
Employment Agreement, Compensation, Shares of Restricted Stock (in shares) | 350,000 | |||||||||||||||
Director, Harold Aubrey de Lavenu [Member] | ||||||||||||||||
Annual Salary | $ 31,200 | |||||||||||||||
Director, Ameen Ferris [Member] | ||||||||||||||||
Annual Salary | $ 31,200 | |||||||||||||||
Restricted Shares Issued for Security Consulting Services [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,870,000 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 1,330,000 | |||||||||||||||
Restricted Shares Issued for Security Consulting Services [Member] | Director,Donald Strilchuck [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 550,000 | |||||||||||||||
Restricted Stock [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 162,500 | 162,500 | 12,059,291 | 225,000 | 12,059,291 | 225,000 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 12,134,291 | 900,000 | 12,209,291 | 1,237,500 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value | $ 117,000 | $ 15,746,822 | $ 162,000 | $ 15,746,822 | $ 162,000 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value | $ 28,760,063 | $ 13,013,241 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | 15,822,572 | 459,000 | $ 15,898,322 | 697,500 | ||||||||||||
Share-based Payment Arrangement, Expense | 14,925,572 | 196,650 | 15,001,322 | 393,300 | ||||||||||||
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | 277,750 | 277,750 | ||||||||||||||
Restricted Stock [Member] | Consulting Fees [Member] | ||||||||||||||||
Share-based Payment Arrangement, Expense | $ 897,000 | $ 162,000 | $ 897,000 | $ 162,000 | ||||||||||||
Restricted Stock [Member] | CONFIEN SAS [Member] | ||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 650,000 | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 897,000 | |||||||||||||||
Restricted Stock [Member] | Director, Harold Aubrey de Lavenu [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,041,250 | |||||||||||||||
Restricted Stock [Member] | Director, Ameen Ferris [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | |||||||||||||||
Restricted Stock [Member] | Directors Ameen Ferris and Harold Aubrey De Lavenu [Member] | ||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 2,816,925 | |||||||||||||||
Restricted Stock [Member] | Richard Boswell [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 2,185,679 | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 3,016,237 | |||||||||||||||
Restricted Stock [Member] | Bahige Chaaban [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 3,106,122 | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 4,286,435 | |||||||||||||||
Restricted Stock [Member] | Brian Payne [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,435,000 | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 1,980,300 | |||||||||||||||
Restricted Stock [Member] | Usamakh Saadikh [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 1,380,000 | |||||||||||||||
Restricted Stock [Member] | Donald Strilchuck [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 341,250 | |||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 470,925 | |||||||||||||||
Restricted Stock [Member] | Director, Alex Tarrabain [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,000,000 | 300,000 | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 899,000 | |||||||||||||||
2017 Equity Compensation Plan [Member] | ||||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 20,000,000 | |||||||||||||||
The 2021 Equity Compensation Plan [Member] | ||||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 20,000,000 |
Note 12 - Stock Based Compens_4
Note 12 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares | Sep. 25, 2020 | Aug. 27, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Non-vested, number of share (in shares) | 425,000 | 2,025,000 | 2,025,000 | |||||
Non-vested, weighted average grant date fair value (in dollars per share) | $ 1.01 | $ 0.76 | $ 0.76 | |||||
Non-vested, weighted average remaining contractual term (Year) | 1 year | 1 year 4 months 6 days | 1 year 6 months | 1 year 6 months 14 days | ||||
Granted, number of share (in shares) | 162,500 | 162,500 | 12,059,291 | 225,000 | 12,059,291 | 225,000 | ||
Granted, weighted average grant date fair value (in dollars per share) | $ 1.31 | $ 0.72 | ||||||
Vested, number of share (in shares) | (12,134,291) | (900,000) | (12,209,291) | (1,237,500) | ||||
Vested, weighted average grant date fair value (in dollars per share) | $ 1.30 | $ 0.68 | ||||||
Forfeited, number of share (in shares) | 0 | 0 | ||||||
Forfeited, weighted average grant date fair value (in dollars per share) | $ 0 | $ 0 | ||||||
Non-vested, number of share (in shares) | 275,000 | 1,012,500 | 275,000 | 1,012,500 | 425,000 | 2,025,000 | ||
Non-vested, weighted average grant date fair value (in dollars per share) | $ 1.01 | $ 0.84 | $ 1.01 | $ 0.84 | $ 1.01 | $ 0.76 |
Note 13 - Net Loss Per Share -
Note 13 - Net Loss Per Share - Antidilutive Securities (Details) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Convertible Debt Securities [Member] | ||||
Antidilutive Securities (in shares) | 2,657,697 | 5,482,166 | 2,631,484 | 5,376,040 |
Note 15 - Fair Value Disclosu_3
Note 15 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Reported Value Measurement [Member] | ||
Cash and cash equivalents | $ 10,840 | $ 1,908 |
Other receivables | 24,629 | 113,999 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 785,618 | 527,379 |
Loans payable – related parties | 1,314,395 | 1,363,354 |
Patent acquisition liability | 302,000 | 1,380,000 |
Convertible notes payable | 2,139,390 | 6,730,448 |
Convertible notes payable – related parties | 2,419,983 | 2,558,681 |
Reported Value Measurement [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 1,299,328 | 1,179,328 |
Reported Value Measurement [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | 17,901 | |
Estimate of Fair Value Measurement [Member] | ||
Cash and cash equivalents | 10,840 | 1,908 |
Other receivables | 24,629 | 113,999 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 785,618 | 527,379 |
Loans payable – related parties | 0 | 0 |
Patent acquisition liability | 302,000 | 1,380,000 |
Convertible notes payable | 3,328,714 | 7,766,663 |
Convertible notes payable – related parties | 0 | 0 |
Estimate of Fair Value Measurement [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 1,299,328 | 1,179,328 |
Estimate of Fair Value Measurement [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | 17,901 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Other receivables | 0 | 0 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 0 | 0 |
Loans payable | 0 | 0 |
Loans payable – related parties | 0 | 0 |
Patent acquisition liability | 302,000 | 0 |
Convertible notes payable | 0 | 0 |
Convertible notes payable – related parties | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Cash and cash equivalents | 10,840 | 1,908 |
Other receivables | 0 | 0 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 0 | 0 |
Loans payable | 0 | 0 |
Loans payable – related parties | 0 | 0 |
Patent acquisition liability | 0 | 0 |
Convertible notes payable | 0 | 0 |
Convertible notes payable – related parties | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Other receivables | 24,629 | 113,999 |
Note receivable – CEN Biotech Ukraine, LLC – related party | 44,859 | 44,859 |
Loans payable | 785,618 | 527,379 |
Loans payable – related parties | 0 | 0 |
Patent acquisition liability | 0 | 1,380,000 |
Convertible notes payable | 3,328,714 | 7,766,663 |
Convertible notes payable – related parties | 0 | 0 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | CEN Biotech Ukraine [Member] | ||
Advances to Subsidiary | $ 1,299,328 | 1,179,328 |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | Emergence Global [Member] | ||
Advances to Subsidiary | $ 17,901 |
Note 16 - Subsequent Events (De
Note 16 - Subsequent Events (Details Textual) | Jul. 13, 2021shares | Jul. 09, 2021USD ($) | Sep. 25, 2020shares | Aug. 27, 2020shares | Aug. 12, 2021USD ($)shares | Jun. 30, 2021shares | Jun. 30, 2020shares | Jun. 30, 2021USD ($)shares | Jun. 30, 2020USD ($)shares | Apr. 20, 2021shares |
Proceeds from Convertible Debt | $ | $ 408,395 | $ 250,000 | ||||||||
Restricted Stock [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 162,500 | 162,500 | 12,059,291 | 225,000 | 12,059,291 | 225,000 | ||||
Clear Com Media, Inc [Member] | ||||||||||
Share Exchange Agreement, Shares to Acquire (in shares) | 10,000 | |||||||||
Share Exchange Agreement, Shares to Issue (in shares) | 4,000,000 | |||||||||
Subsequent Event [Member] | ||||||||||
Proceeds from Convertible Debt | $ | $ 20,000 | |||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 52,631 | |||||||||
Subsequent Event [Member] | Chief Technology Officer [Member] | ||||||||||
Annual Salary | $ | $ 31,200 | |||||||||
Subsequent Event [Member] | Patrick Keane [Member] | Restricted Stock [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 200,000 | |||||||||
Subsequent Event [Member] | Daniel Scott [Member] | Restricted Stock [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 300,000 | |||||||||
Subsequent Event [Member] | Conversion of Notes Payable to Common Stock [Member] | ||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 18,873 | |||||||||
Debt Conversion, Original Debt, Amount | $ | $ 30,196.80 |